PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33164274-9	2021	Reduction in the expression of vimentin, beta-catenin, and HOTAIR was detected as the result of metformin treatment, but the snail showed a constant expression.	Metformin	96-105	vimentin	Homo sapiens	31-39	
35178358-0	2021	Metformin is a Novel Suppressor for Vimentin in Human Gastric Cancer Cell Line.	Metformin	0-9	vimentin	Homo sapiens	36-44	
35178358-3	2021	In this study, AGS gastric cancer cells were treated with metformin and vimentin-specific siRNA (vim-siRNA) for 48 h. The impact of metformin and vim-siRNA on vimentin downregulation in AGS cells were analyzed by quantitative PCR and Western blot.	Metformin	58-67	vimentin	Homo sapiens	159-167	
35178358-3	2021	In this study, AGS gastric cancer cells were treated with metformin and vimentin-specific siRNA (vim-siRNA) for 48 h. The impact of metformin and vim-siRNA on vimentin downregulation in AGS cells were analyzed by quantitative PCR and Western blot.	Metformin	132-141	vimentin	Homo sapiens	159-167	
35178358-5	2021	The results showed that inhibition of vimentin due to metformin was comparable with the vim-siRNA.	Metformin	54-63	vimentin	Homo sapiens	38-46	
35178358-7	2021	Our finding for the first time indicated that metformin can be an alternative to specific siRNA for inhibition of vimentin expression and migration of AGS cell line.	Metformin	46-55	vimentin	Homo sapiens	114-122	
30569135-3	2019	Additionally, metformin attenuated the EMT process, characterized by a decrease of mesenchymal marker Vimentin and an increase in the expression of an epithelial marker.	Metformin	14-23	vimentin	Homo sapiens	102-110	
30625181-6	2019	Similarly, metformin treatment suppressed expressions of anti-apoptotic genes BCL2 and Bcl-xL, and mesenchymal genes vimentin, N-cadherin, Zeb1 and Zeb2 with simultaneous enhancement of apoptotic caspase 3 and Bax, and epithelial genes E-cadherin and keratin 19 expressions, confirming an inhibitory effect of metformin in tumorigenesis.	Metformin	11-20	vimentin	Homo sapiens	117-125	
31939444-10	2019	Metformin attenuated transforming growth factor-beta1 induced decrease of E-cadherin and increase of Vimentin proteins.	Metformin	0-9	vimentin	Homo sapiens	101-109	
30625181-9	2019	Similarly, cholesterol treatment inverted metformin-reduced several gene expressions (e.g., Bcl-xL, BCL2, Zeb1, vimentin, and BMI-1).	Metformin	42-51	vimentin	Homo sapiens	112-120	
30017802-8	2018	The up-regulation of E-cadherin and the down-regulation of vimentin for both SW480 and HCT116 cells revealed the anti-EMT abilities of metformin.	Metformin	135-144	vimentin	Homo sapiens	59-67	
28011481-6	2017	A low dose of metformin significantly increased anoikis and inhibited migration/ invasion of CCA cells that was in concert with the decrease of vimentin, matrix metalloproteinase (MMP)-2 and -7.	Metformin	14-23	vimentin	Homo sapiens	144-152	
29635803-9	2018	Metformin inhibited vimentin expression in both normal and tumor cells.	Metformin	0-9	vimentin	Homo sapiens	20-28	
28043910-3	2017	In this study, we demonstrated that metformin is capable of inhibiting prostate cancer cell migration and invasion by repressing EMT evidenced by downregulating the mesenchymal markers N-cadherin, Vimentin, and Twist and upregulating the epithelium E-cadherin.	Metformin	36-45	vimentin	Homo sapiens	197-205	
28042775-6	2017	RESULTS: There was a lower protein expression of ROCK-1, vimentin, CD44 and CD24 in both cell lines after treatment with metformin and Y27632.	Metformin	121-130	vimentin	Homo sapiens	57-65	
28744307-1	2017	OBJECTIVES: We aimed to explore the association between metformin treatment and epithelial-mesenchymal transition (EMT) phenotype and further appraise the prognostic values of metformin and EMT markers E-cadherin and vimentin for colorectal cancer (CRC) in clinical practice.	Metformin	56-65	vimentin	Homo sapiens	217-225	
27643646-8	2016	Metformin reduced EMT in the cell lines and regulated the expression of the EMT-related epithelial markers, E-cadherin and Pan-keratin; the mesenchymal markers, N-cadherin, fibronectin, and vimentin; and the EMT drivers, Twist-1, snail-1, and ZEB-1.	Metformin	0-9	vimentin	Homo sapiens	190-198	
25201727-7	2014	Metformin could inhibit TGF-beta-induced EMT in Vcap cells, as manifested by inhibition of the increase of N-cadherin (p=0.013), Vimentin (p=0.002) and the decrease of E-cadherin (p=0.0023) and beta-catenin (p=0.034) at mRNA and protein levels.	Metformin	0-9	vimentin	Homo sapiens	129-137	
26718286-13	2015	Metformin was also associated with a reduction of snail2, twist, and vimentin in CD44(+)CD117(+) ovarian CSCs in vivo.	Metformin	0-9	vimentin	Homo sapiens	69-77